Home Inherited Disease and Carrier Screening Sickle Cell Genetic Test: HBB Gene, Trait, Disease, and Results

Sickle Cell Genetic Test: HBB Gene, Trait, Disease, and Results

By
Vita Library
-
4
Learn how HBB genetic testing distinguishes sickle cell trait from HbSS, HbSC, and sickle beta-thalassemia and clarifies newborn and family results.

A sickle cell genetic test analyzes the HBB gene, which provides instructions for beta-globin, one part of adult hemoglobin. The classic sickle variant changes one amino acid in beta-globin and produces hemoglobin S, or HbS. One HbS allele usually causes sickle cell trait. Two clinically significant beta-globin alleles—including at least one HbS allele—can cause sickle cell disease (SCD), such as HbSS, HbSC, or sickle beta-thalassemia.

DNA testing is only one part of diagnosis. Hemoglobin analysis by high-performance liquid chromatography, electrophoresis, capillary methods, or isoelectric focusing shows which hemoglobin proteins are present and in what proportions. A complete blood count and red-cell indices add important context. Molecular testing is especially useful when protein results are ambiguous, the person was recently transfused, a newborn pattern needs clarification, or prenatal testing requires exact familial variants. The words “positive for sickle” are not enough: the report must distinguish trait from disease, identify any second HBB variant, and account for transfusion, age, and treatment.

  • Sickle cell trait usually means one HbS allele and one usual HBB allele.
  • Sickle cell disease requires HbS plus another disease-causing beta-globin allele.
  • HbSS, HbSC, and HbS/beta-thalassemia are different SCD genotypes.
  • Newborn hemoglobin patterns need prompt confirmatory testing because fetal hemoglobin dominates at birth.
  • Recent transfusion can mask or dilute a person’s own hemoglobin pattern.
  • Partner testing is essential when one person has HbS or another clinically significant hemoglobin variant.

Table of Contents

What the HBB test detects

Hemoglobin carries oxygen inside red blood cells. Adult hemoglobin A contains two alpha-globin and two beta-globin chains. The HBB gene encodes beta-globin. The sickle allele produces a beta-globin chain that can polymerize when deoxygenated, making red cells rigid and prone to hemolysis and blood-vessel blockage.

The classic HbS change is commonly described at the protein level as p.Glu6Val under traditional mature-protein numbering. Modern genetic reports may use p.Glu7Val because the reference sequence counts the initiating methionine. Both can refer to the same sickle variant, so the DNA notation and transcript should be checked rather than assuming the reports conflict.

An HBB test may look for:

  • The HbS variant
  • Hemoglobin C, D-Punjab, O-Arab, E, and other structural beta-globin variants
  • Beta-zero thalassemia variants that stop beta-globin production
  • Beta-plus thalassemia variants that reduce beta-globin production
  • Promoter, splice, small insertion/deletion, and coding variants
  • Larger deletions or duplications when the assay includes copy-number analysis

A targeted sickle test checks only the known HbS position. It can answer a narrow question quickly but will not identify every second variant that could produce disease. Comprehensive HBB sequencing is more appropriate when a person has HbS plus an unexplained hemoglobin pattern, microcytosis, a family history of thalassemia, or a reproductive partner with another beta-globin finding.

Some hemoglobin disorders involve HBA1 and HBA2, the alpha-globin genes, rather than HBB. Alpha-thalassemia can change red-cell size and may modify laboratory findings in someone with HbS, but an HBB-only test does not detect most alpha-globin deletions. A broad hemoglobinopathy evaluation may therefore combine protein analysis with HBB sequencing and alpha-globin testing.

A single-gene test should clearly state whether it included sequencing, deletion/duplication analysis, and only the sickle variant or the full HBB gene. This technical distinction directly affects how reassuring a negative result is.

Sickle cell trait versus sickle cell disease

Sickle cell trait and sickle cell disease are not interchangeable.

Sickle cell trait

A person with sickle cell trait typically has one HbS allele and one usual beta-globin allele, often written HbAS. Most red cells contain more hemoglobin A than hemoglobin S, and the person does not have the chronic hemolytic anemia or recurrent vaso-occlusive complications of SCD.

Trait is generally compatible with normal health and life activities. Rare complications can occur under extreme physiologic stress or in specific settings, including severe dehydration, very low oxygen, high altitude, intense exertion, or certain kidney and eye conditions. These possibilities should be discussed accurately without describing all carriers as ill.

Trait matters most consistently for reproductive risk. A person with HbAS can pass either the usual HBB allele or the HbS allele to each child. The child’s outcome depends on the other biological parent’s hemoglobin genes.

HbSS disease

HbSS, often called sickle cell anemia, means the person inherited HbS from both parents. It commonly causes chronic hemolytic anemia and risk of pain episodes, acute chest syndrome, infection, stroke, splenic dysfunction, kidney disease, and other complications. Severity varies widely.

HbSC disease

HbSC means one HbS allele and one HbC allele. It is a form of sickle cell disease, not “double trait.” Many people have higher hemoglobin levels and fewer hemolytic complications than those with HbSS, but clinically important pain, retinopathy, avascular necrosis, pregnancy complications, and other organ effects can occur.

Sickle beta-thalassemia

HbS/beta-zero thalassemia combines HbS with an HBB allele that produces no beta-globin. Its clinical pattern can resemble HbSS. HbS/beta-plus thalassemia combines HbS with an allele that produces reduced beta-globin; severity varies according to how much hemoglobin A is produced.

Microcytosis can support beta-thalassemia but is not definitive because iron deficiency and alpha-thalassemia also lower red-cell size. Molecular identification of the beta-thalassemia allele can resolve whether an “S plus microcytosis” pattern is true sickle beta-thalassemia.

Other combinations

HbS can combine with HbD-Punjab, HbO-Arab, or other pathogenic beta-globin variants to cause clinically significant sickling disorders. The risk cannot be inferred from the word “variant” alone. The exact hemoglobin and HBB result must be interpreted by a hematology or genetics professional.

How hemoglobin tests and DNA work together

Protein-based hemoglobin analysis is usually the first-line diagnostic tool because it shows the functional products circulating in blood. Genetic testing clarifies the underlying alleles.

High-performance liquid chromatography, capillary electrophoresis, isoelectric focusing, and hemoglobin electrophoresis separate hemoglobins according to physical properties. Laboratories often use two complementary methods when confirming a significant result because some variants migrate or elute together.

The report may list percentages of hemoglobin A, S, F, A2, C, or other fractions. Interpretation depends on age and treatment:

  • Newborns have mostly fetal hemoglobin, HbF.
  • Hydroxyurea can raise HbF.
  • Transfusion adds donor HbA and dilutes the patient’s hemoglobin.
  • Iron deficiency can influence indices and some fraction measurements.
  • Beta-thalassemia can raise HbA2, although recent transfusion or technical overlap may obscure it.

A sickle solubility test can detect the presence of HbS in many older children and adults, but it cannot distinguish trait from disease and is unreliable in newborns. A positive solubility screen must be followed by definitive hemoglobin analysis.

DNA testing becomes particularly helpful when:

  1. The hemoglobin pattern is ambiguous or two variants overlap on the platform.
  2. A recent transfusion makes protein percentages unreliable.
  3. HbS is present with microcytosis and beta-thalassemia is suspected.
  4. Newborn screening suggests SCD but exact genotype is unclear.
  5. A family needs precise variants for prenatal or preimplantation testing.
  6. The person has undergone stem-cell transplantation, which complicates both blood DNA and hemoglobin interpretation.

The complete blood count adds context. HbSS and HbS/beta-zero disease often cause anemia and reticulocytosis. HbSC may have a higher hemoglobin concentration. Low mean corpuscular volume can suggest thalassemia or iron deficiency. No single index establishes genotype.

A genetic result should agree with the protein pattern. For example, a nontransfused adult with one HbS allele and one normal HBB allele should usually have both HbA and HbS. A person with two HbS alleles should not produce HbA unless transfused or successfully treated with donor-derived stem cells. Discordance should trigger a review of sample identity, transfusion history, transplant history, and assay limitations.

Understanding newborn screening results

Newborn screening detects hemoglobin patterns before most infants develop symptoms. Early identification allows preventive care, including infection prevention, family education, and specialist follow-up. A screen is not the final diagnosis.

Newborn reports commonly list hemoglobins in order of abundance. Because HbF predominates at birth, the letter F often appears first.

FS pattern

An FS pattern means fetal hemoglobin and hemoglobin S are present, with no detectable hemoglobin A. This can represent HbSS, HbS/beta-zero thalassemia, or less common genotypes. Confirmatory protein and molecular testing may be needed to distinguish them.

FSA pattern

FSA shows HbF, HbS, and some HbA. It may suggest HbS/beta-plus thalassemia, but transfusion, prematurity, and assay details can affect the pattern. The amount of HbA and follow-up testing matter.

FSC pattern

FSC suggests HbSC disease. The infant has fetal hemoglobin plus hemoglobin S and hemoglobin C. Confirmation should occur promptly.

FAS pattern

FAS usually indicates sickle cell trait because HbA exceeds HbS. It still needs communication and, according to the screening program, confirmatory testing. Families should not be told the baby has sickle cell disease.

Other patterns

Patterns such as FSD, FSE, or FSO can reflect HbS with another beta-globin variant. Laboratories use local reporting conventions, and not every letter sequence has identical meaning across programs. The screening program or pediatric hematologist should interpret the actual report.

Prematurity and transfusion complicate newborn results. A transfused baby may show donor HbA that masks disease, and some programs request a repeat sample months after the last transfusion. Genetic testing can clarify the infant’s inherited genotype without waiting for donor red cells to disappear, provided the DNA sample itself is appropriate.

Confirmatory evaluation should occur within the program’s recommended timeline. Families of an infant with a disease-suggestive pattern need rapid referral to pediatric hematology. Waiting for symptoms is unsafe because infection risk can begin before the child appears ill.

Newborn screening may also identify trait. Trait is not a failed or false screen; it is an important carrier finding. Parents should receive clear counseling, their own hemoglobin status should be offered or reviewed, and the child should be told about the result at an appropriate age. A newborn screening guide can help families understand why screening and confirmation are separate steps.

Interpreting HBB genetic result categories

The laboratory report should identify each HBB variant, its classification, zygosity, and expected hemoglobin effect.

One HbS allele

One HbS allele with no second pathogenic HBB finding usually supports sickle cell trait. Hemoglobin analysis should show a compatible pattern unless age, transfusion, or transplant changes it. A negative full-gene result for a second allele is more informative than a test that looked only for HbS.

Two HbS alleles

Two HbS alleles confirm the HbSS genotype. In standard terminology, the person is homozygous for the sickle variant. Clinical severity still cannot be read directly from the genotype.

HbS plus another pathogenic HBB variant

The second allele determines the disease subtype. HbC supports HbSC; a beta-zero variant supports HbS/beta-zero thalassemia; a beta-plus variant supports HbS/beta-plus thalassemia. Other structural variants require gene-specific and protein-based interpretation.

Phase matters if more than two variants are reported. Variants in cis are on the same chromosome copy; variants in trans are on opposite copies. Family testing may be needed when complex alleles or multiple beta-globin changes are present.

Variant of uncertain significance

A VUS is not established as disease-causing. A person with HbS plus an HBB VUS should not automatically be diagnosed with SCD from DNA alone. Hemoglobin fractions, red-cell indices, family segregation, functional data, and variant reclassification may resolve the result. A VUS explanation can help prevent overinterpretation.

Negative result

A negative HBB test means no reportable variant was detected within the assay’s scope. If a reliable hemoglobin analysis shows HbS, a negative targeted test may have used the wrong method, the sample may be mismatched, or the report may be misunderstood. If the question is alpha-thalassemia, an HBB-negative result does not address it.

Benign or modifier findings

Some variants alter fetal hemoglobin or red-cell properties without causing SCD by themselves. Genetic modifiers in BCL11A, the beta-globin cluster, alpha-globin genes, and elsewhere can influence severity at a population level. Most routine diagnostic reports do not use these modifiers to predict one person’s course with precision.

The report should not use broad terms such as “carrier of sickle cell disease” without stating the allele. A person can carry HbS, HbC, beta-thalassemia, or another variant, and reproductive combinations differ.

Inheritance, partner testing, and pregnancy

HBB-related sickle disorders follow an autosomal recessive pattern, but the possible child genotypes depend on both parents’ exact alleles.

If one parent has HbAS and the other has usual adult hemoglobin with no pathogenic HBB variant, each child has a 50% chance of trait and a 50% chance of inheriting neither HbS allele. The child is not expected to have SCD from that pairing.

If both parents have HbAS, each pregnancy has:

  • A 25% chance of HbSS disease
  • A 50% chance of HbAS trait
  • A 25% chance of no HbS allele

If one parent has HbAS and the other has HbAC, each pregnancy has a 25% chance of HbSC disease, a 25% chance of HbAS, a 25% chance of HbAC, and a 25% chance of inheriting neither variant. If the partner carries beta-thalassemia, HbS/beta-thalassemia is possible.

This is why partner testing should not be limited to the sickle variant. A complete blood count and hemoglobin analysis can identify many clinically relevant variants, and molecular testing can clarify uncertain or thalassemia-associated findings. Universal hemoglobinopathy testing during preconception or pregnancy avoids relying only on race or ethnicity, which can miss carriers in diverse families.

An affected person with HbSS passes an HbS allele to every biological child. Whether the child has trait or disease depends on the partner. A person with HbSC can pass either HbS or HbC. A person with HbS/beta-thalassemia can pass HbS or the beta-thalassemia allele.

Reproductive options include natural conception, prenatal diagnosis using chorionic villus sampling or amniocentesis, and in vitro fertilization with preimplantation genetic testing for a monogenic condition. Testing requires clear parental genotypes. Cell-free DNA screening for fetal sickle status is not equivalent to diagnostic fetal testing and availability and validation vary.

Pregnancy in a person with SCD carries medical risks that require high-risk obstetric and hematology care. A carrier pregnancy is not managed as SCD solely because the pregnant person has trait, but trait and the partner’s status remain important for counseling. General information about prenatal genetic testing can support informed discussion.

What results can and cannot predict

Genotype provides important broad information. HbSS and HbS/beta-zero disease often have more severe hemolysis than HbSC or many HbS/beta-plus genotypes. HbSC carries particular risks, including proliferative retinopathy. The amount of beta-globin produced by a beta-plus allele can influence phenotype.

But genotype is not a complete prognosis. People with the same HBB combination can have very different pain frequency, stroke risk, kidney disease, lung complications, and life course. Fetal hemoglobin level, alpha-thalassemia, other genetic modifiers, access to preventive care, treatment, infection, environment, and chance all contribute.

A standard HBB test cannot predict the exact number of pain episodes, age of organ damage, or response to every medicine. Clinical monitoring remains essential. In children with SCD, transcranial Doppler screening, vaccination, infection prevention, laboratory monitoring, and disease-modifying treatment are based on evidence and individual clinical factors rather than DNA alone.

HBB genotype can matter for advanced therapy eligibility, but it is only one criterion. Stem-cell transplantation and gene-based therapies require detailed assessment of disease severity, age, organ function, donor or product considerations, fertility, treatment risks, and access. A person should not assume that any positive HBB result qualifies for a specific therapy.

Trait also should not be interpreted as a prediction of SCD symptoms. A person with HbAS does not convert to HbSS later in life. The genotype is stable. If a person with trait has chronic anemia, repeated pain, or organ problems, clinicians should investigate other causes and confirm that the original result was complete.

For athletes, military personnel, and workers in extreme conditions, trait information can support precautions such as gradual conditioning, hydration, rest, and prompt response to heat illness. Policies should be evidence-based and should not stigmatize or automatically exclude people with trait.

The genetic result is best used to name the condition, guide family risk, resolve an ambiguous phenotype, and support appropriate care. Longitudinal clinical data—not the variant alone—show how disease is behaving.

Follow-up, transfusion effects, and common pitfalls

Several practical details can prevent a correct test from being misread.

Recent transfusion

Donor red cells can introduce HbA and lower the measured percentage of HbS for months. Protein analysis may therefore resemble trait or a milder genotype. The laboratory must know the transfusion date. HBB testing from the patient’s white-cell DNA can often identify the inherited genotype despite red-cell transfusion.

Stem-cell or bone marrow transplantation

After successful allogeneic transplantation, blood-forming cells and blood DNA may come from the donor. A blood HBB test can therefore report the donor genotype, not the patient’s inherited genotype. Pretransplant records are ideal. If germline confirmation is needed, the laboratory may request cultured skin fibroblasts or another non-hematopoietic sample.

Iron deficiency and alpha-thalassemia

Both can cause microcytosis. Iron studies should be checked before assuming beta-thalassemia. Alpha-globin testing may be needed when microcytosis persists with normal iron and no explanatory HBB variant.

Medication and age

Hydroxyurea raises HbF and can change cell size. Infants naturally have high HbF. These factors affect protein percentages but do not change inherited HBB variants.

Outdated terminology

Older records may say “sickle cell anemia” for any sickling disorder or may label HbSC as trait. The exact hemoglobin fractions and DNA findings should be re-reviewed. Variant numbering can also differ between traditional and current genetic nomenclature.

Incomplete carrier testing

A negative test for the HbS variant does not rule out HbC, beta-thalassemia, or other hemoglobinopathy carrier states. Reproductive screening should use a method suited to the full question, not only a common-variant assay.

Lost newborn results

Adults may remember being told they “carry sickle” without documentation. Repeat hemoglobin analysis is reasonable. A clear report helps prevent mistakes during pregnancy, surgery, military or athletic evaluation, and family testing.

People with confirmed SCD should be connected to comprehensive hematology care. Infants need rapid preventive management. People with trait should receive accurate education and partner-testing information without being placed on an SCD treatment pathway.

Urgent care is needed for fever in a child with SCD, chest pain or breathing difficulty, symptoms of stroke, severe anemia, prolonged painful erection, rapidly enlarging spleen in a child, or severe uncontrolled pain. A genetic report explains risk but does not replace emergency assessment.

References

Disclaimer

This article is for general education and does not diagnose sickle cell trait or disease or replace hemoglobin analysis, blood counts, and specialist interpretation. HBB findings must be reviewed with transfusion, transplant, age, treatment, and family history by qualified hematology and genetics professionals. Fever in a child with SCD, chest pain, breathing difficulty, stroke symptoms, severe anemia, or other acute complications requires urgent medical care.

RELATED ARTICLESMORE FROM AUTHOR